Hey, it's Kramer, and this is my morning take on the market from today's CNBC Investing Club

morning meeting.

I think the Dow's been going down seven straight days in part because we think that the

Fed's not going to be encouraged about rate cuts.

Yeah, there has been a lot of poor breath lately, which basically means there's been

more stocks falling than rising. It has

been a nice mag seven move the last couple days. It sure has. But this has also led to the

oscillator becoming oversold. Right, minus 4.1. So we're now looking to buy. Yep. And we bought

something this morning that I feel really terrific about, Bristol Myers. Yeah, bought Bristol

Myers. You know, stock, we pointed this out on

Thursday, basically given up about half those gains from that, the AVVie, from the AVV failure

right there, which basically meant that their schizophrenia drug, Kibenfi, had a, it's basically,

it's only them. I was thinking that it was going to be a $10 billion drug. I now think it could be $15 billion. And the reason to say that is if you add up all the convulsants that are being used, there's nothing to do for, 30 years for schizophrenic or for bipolar. This works. Clueteroputoputics works. Yeah, I know when we bought, when we started the

position here, J.P. Morgan was saying maybe mid to high single digit billion peak sales. Jeffries,

they upgrade Bristol Myers to a buy this morning, $70 price target. They're modeling peak sales of

11 billion. So again, we're talking numbers well above street. They're also getting a little

bit more comfortable around what else is in Bristol's pipeline.

And then the valuation, they think earnings, the trough, which is basically, remember, they have

a big patent cliff here.

But they think the bottom earnings.

Undeniable cap patent cliff.

But they think because of Kbenfi and some other things that Bristol will, you know,

...